Cholangiocarcinoma News

Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study

September 2022, Vol 3, No 3

The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1 At the 2022 ASCO annual meeting, data were presented from a prespecified subgroup analysis that assessed efficacy outcomes for patients enrolled in Asia and the rest of the world (RoW).

In the trial, 685 eligible patients were randomly assigned 1:1 to receive durvalumab (n = 341; 1500 mg once every 3 weeks [Q3W]) or placebo (n = 344) in combination with GemCis (gemcitabine 1000 mg/m2; cisplatin 25 mg/m2, days 1 and 8, Q3W) for up to 8 cycles, followed by durvalumab (1500 mg every 4 weeks) or placebo monotherapy until disease progression or unacceptable toxicity. The prespecified subgroup analysis assessed 2 cohorts: those enrolled in Asia (China, Hong Kong, India, Japan, South Korea, Taiwan, Thailand) or RoW (Europe [Bulgaria, France, Italy, Poland, Russia, Turkey, United Kingdom], North America [United States], and South America [Argentina, Chile]).

A total of 374 patients were included in the Asia cohort (54.6%), and 311 (45.4%) patients were in the RoW cohort. Some differences in baseline characteristics were seen between the 2 regional groups for durvalumab-treated patients, including recurrent disease (Asia, 23%; RoW, 14.5%), ECOG performance status 1 (Asia, 59.1%; RoW, 41.2%), and metastatic disease (Asia, 89.3%; RoW, 82.0%). In addition, in the placebo arm, a higher proportion of patients in Asia received subsequent anticancer therapies than in the RoW group (53.6% vs 43.9%). Median duration of follow-up in censored patients was longer in Asia versus the RoW in both groups (durvalumab, 14.8 months vs 13.0 months; placebo, 13.8 months vs 12.1 months).

Overall, regional-level analysis showed that outcomes were generally similar and approximated the overall populations for Asia, Europe, and North America, with OS showing a trend in favor of durvalumab compared with placebo across most regions except South America, where placebo performed better. It is notable that OS was significantly better with the addition of durvalumab to GemCis in Asia, suggesting that the impact on OS of durvalumab in Asia was greater than what was seen in the RoW cohort. Despite a higher prevalence of hepatitis B infection in patients enrolled in Asia, survival outcomes were similar in patients with and without viral hepatitis.

The safety profile of durvalumab plus GemCis was similar between the 2 regional groups and was generally manageable. Grade 3/4 adverse events were predominantly hematologic for both arms and regions and similar for Asia (durvalumab, 78.5%; placebo, 78.6%) and RoW (durvalumab, 72.7%; placebo, 76.7%).

According to the researchers, results of the subgroup analyses showed that “despite some regional differences in baseline prognostic characteristics, OS trends favored durvalumab compared with placebo in both Asia and RoW, supporting the use of durvalumab plus GemCis as a potential new first-line treatment option for all patients with BTCs.”

Reference

  1. Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8). Published online June 1, 2022.

Source: Vogel A, Chen L-T, He AR, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (BTC). Abstract 4075.

Related Items

CCA Summit Live from ASCO 2023
By Renuka V. Iyer, MD; Vaibhav Sahai, MBBS, MS
Videos
On June 4, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO).
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP
September 2022, Vol 3, No 3
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs
September 2022, Vol 3, No 3
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial
September 2022, Vol 3, No 3
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: